Liposomes and lipid nanoparticles (LNPs) have emerged as leading materials for the encapsulation and in vivo delivery of drugs, therapeutic agents, mRNA, and other APIs for a wide range of applications including vaccine development nanomedicines and gene therapy.
Dolomite’s leading microfluidic technology offers an unique automated nanoparticle generation platform for the generation of homogeneous, controllable, and reproducible LNPs. The ability to control LNP size from as small as 20 nm allows for a wide range of end-user applications. Key features of the Automated Nanoparticle (ANP) System include running protocols with importable experiment tables to generate formulation libraries, and the ability to run in continuous mode to generate large samples once the synthesis is optimised.
Read more about how Microfluidic technology enables increased production control over the lipid’s/liposome’s physical properties, especially in terms of small mean size, narrow size distribution and lamellarity.
Read our new Application Note on the controlled synthesis of lipid nanoparticles using the ANP System and learn about the research done by our Experts on the key parameters involved in tuning LNPs’ size, and a comparison between the protocol and continuous mode to demonstrate the transferability of the process parameters for bulk production of LNPs.
